Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SBLOF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5600.34 Med: 10.98 Max: 53.24
Current: 7.64
During the past 13 years, the highest EV-to-EBITDA of Shin Nippon Biomedical Laboratories was 53.24. The lowest was -5600.34. And the median was 10.98.
SBLOF's EV-to-EBITDA is ranked better than 74.36% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.77
vs SBLOF: 7.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shin Nippon Biomedical Laboratories's PE Ratio (TTM) for today is calculated as:
Shin Nippon Biomedical Laboratories's share price for today is $9.1608.
Shin Nippon Biomedical Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.707.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's EV-to-EBITDA falls into.
Shin Nippon Biomedical Laboratories's current Enterprise Value is $478.6 Mil.
Shin Nippon Biomedical Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $64.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a EV-to-EBITDA of 7.44 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shin Nippon Biomedical Laboratories. This is 32% below median its historical median of 10.98. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #30 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 25.6%.
Is Shin Nippon Biomedical Laboratories' EV-to-EBITDA too high?
Shin Nippon Biomedical Laboratories' current EV-to-EBITDA of 7.44 is 32% below median its 10-year median of 10.98. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.77. Shin Nippon Biomedical Laboratories' value of 7.44 is 49.6% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #30 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #30 out of 117 companies for EV-to-EBITDA. This puts Shin Nippon Biomedical Laboratories in the upper half of its industry. The industry median EV-to-EBITDA is 14.77. Shin Nippon Biomedical Laboratories' value of 7.44 is 49.6% below this benchmark. While the company's 10-year median is 10.98 vs. the industry median of 14.77, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.77, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current EV-to-EBITDA of 7.44 is 49.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shin Nippon Biomedical Laboratories. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current EV-to-EBITDA is 7.44, which is 32% below median its own 10-year median of 10.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current EV-to-EBITDA of 7.44. The stock's GF Value™ is $12.76, compared to a current price of $9.16 — trading 28.2% below its estimated fair value. The current EV-to-EBITDA is 7.44, which is 32% below median its 10-year median of 10.98 and 49.6% below the Medical Diagnostics & Research industry median of 14.77. Shin Nippon Biomedical Laboratories' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current EV-to-EBITDA is 7.44 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 28.2% below its estimated GF Value™ of $12.76.
Key valuation signals for SBLOF:
EV-to-EBITDA: 7.44 (32% below median its 10-year median of 10.98)
GF Value™: $12.76 vs. price of $9.16 (28.2% below fair value)
Industry Position: 49.6% below the Medical Diagnostics & Research median (#30 of 117)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
73GF Score
Get the complete analysis for SBLOF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
